May 23, 2013 9:40 PM ET

Pharmaceuticals

Company Overview of Icon Bioscience, Inc.

Company Overview

Icon Bioscience, Inc. develops and commercializes ophthalmic pharmaceuticals products. Its products include IBI-20089, an injectable intraocular sustained release product for the delivery of triamcinolone acetonide; IBI-10090, a product for injection into the anterior chamber of the eye and use in conjunction with cataract surgery; and melphalan intraocular injection for the treatment of retinoblastoma. The company’s products are also used for the treatment of various ophthalmic diseases, including glaucoma, wet age related macular degeneration (AMD), diabetic macular edema, uveitis, and cornea transplant rejection. Icon Bioscience, Inc. was incorporated in 2004 and is based in Sunnyvale, Ca...

Detailed Description

1253 Reamwood Avenue

Sunnyvale, CA 94089

United States

Founded in 2004

Phone:

408-734-8188

iconbioscience.com

Key Executives for Icon Bioscience, Inc.

Chief Executive Officer
Founder and Chairman
Age: 80
Vice President of Clinical Development
Manufacturing & Operations Advisor
Advisor
Age: 65
Compensation as of Fiscal Year 2012.

Icon Bioscience, Inc. Key Developments

U.S. Food & Drug Administration Grants Orphan Drug Designation for Icon's Melphalan Intraocular Injection
Jan 3 13

Icon Bioscience, Inc. announced that melphalan intraocular injection, the company's investigational product for the treatment of retinoblastoma, has been granted Orphan Drug Designation by the U.S. Food & Drug Administration (FDA). Orphan Drug Designation is generally granted to drugs or biologics intended for treatment of rare diseases and disorders, that is those affecting fewer than 200,000 people in the U.S. This designation conveys special incentives to the sponsor, including tax credit for 50% of the cost of clinical trials, prescription drug user fee waiver, and seven years of U.S. market exclusivity for the drug or biologic upon FDA approval.

Icon Bioscience, Inc. Appoints Wendy Yee Murahashi as Vice President, Clinical Development
Dec 7 11

Icon Bioscience, Inc. announced that Wendy Yee Murahashi, M.D. has joined the management team of IBI as Vice-President, Clinical Development. Dr. Murahashi will lead Icon Bioscience's clinical development programs based on IBI's proprietary Verisome(R) drug delivery technology. Prior to joining Icon Bioscience, Dr. Murahashi was a Medical Director at Genentech/Roche, Inc.

Similar Private Companies By Industry

Company Name Region
Adamas Pharmaceuticals, Inc. United States
American Sterilizer Company United States
SynChem, Inc. United States
EPi-Q, Inc. United States
GCTRO Inc. United States

Recent Private Companies Transactions

Type
Date		 Target
No transactions available in the past 12 months.
Report Data IssueReport Data Issue
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Icon Bioscience, Inc., please visit iconbioscience.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.

Close